Our Blog

Mesoblast expands JCR partnership to brain disease in newborns

11 Jun 2019 – Mesoblast (ASX:MSB) has today announced it has expanded its partnership with JCR Pharmaceuticals in Japan (to the use of mesenchymal stem cells (MSCs)) for the treatment of newborns who lack sufficient blood supply and oxygen to the brain or HIE.


Source: Finance News Network

Share this post